Diplomat 2025: Sales Still Grew, but 2026 Already Looks Like a Capital Test

Getting to Know the Company

Diplomat is not a one-brand story and not a one-country story. It is an import, marketing, and distribution platform for fast-moving consumer goods, FMCG, operating in Israel, South Africa, Georgia, New Zealand, and Cyprus, with Cyprus also serving Greece and Romania. The economics are built on two clear engines: strong relationships with global suppliers, and a commercial and logistics system that can push products into thousands of points of sale.

What is working right now is easy to see. Revenue rose in 2025 to NIS 3.754 billion, gross profit rose to NIS 809.6 million, and Israel remained the core engine with NIS 2.255 billion of revenue and NIS 105.3 million of segment operating profit. Cyprus also kept growing, and the platform still looks broader and more diversified than a typical Israeli distribution company.

But the superficial reading misses the real issue. The question is no longer whether Diplomat knows how to grow. It does. The question is whether this growth still converts into cash and flexibility, or whether it now requires more working capital, more inventory, more credit, and more execution than the headline revenue line suggests. When operating cash flow falls to NIS 74.0 million from NIS 199.0 million, while receivables and inventory keep rising and the company is simultaneously funding a new logistics center in Caesarea and a potential acquisition in Mexico, the bottleneck is no longer sales. It is capital.

That is also why the story matters now. With a market cap of about NIS 1.48 billion, Diplomat is no longer a small company that can be given a free pass for a messy investment year. For the read to improve over the next 2 to 4 quarters, the company needs to show that receivables and inventory can stabilize, that the weak fourth quarter was not the start of a broader margin problem, and that if Mexico advances, it does so in a structure that does not stretch the balance sheet further.

Four non-obvious findings right up front:

• Net profit looked stronger than the operating core. Finance income jumped to NIS 35.1 million mainly because of roughly NIS 29 million from the put-option realization in Neve Pharma, while normalized operating profit actually weakened.
• The real problem in 2025 was not revenue, but cash conversion. Receivables rose to NIS 501.9 million, inventory rose to NIS 561.0 million, and operating cash flow dropped by more than 60%.
• New Zealand is small in revenue but large as a warning sign. NIS 262.2 million of sales produced only NIS 145 thousand of segment operating profit, in a market where a handful of retailers hold unusual pricing power.
• Caesarea and Mexico together change the conversation. Each move can make strategic sense, but both together turn 2026 from a normal growth year into a capital test.

Diplomat's economic map looks like this:

What matters in that map is not just diversification, but the quality of diversification. Israel still carries most of the value, Cyprus looks efficient, and New Zealand currently adds almost only volume. This is not a company without geographic spread, but it is also not one where all territories contribute with the same economic quality.

Events and Triggers

The first trigger is Caesarea, and it is no longer just a logistics project. Diplomat signed the Caesarea logistics-center arrangement back in 2021 on about 80 dunams, for a lease term of 24 years and 11 months. In 2025 it already paid roughly NIS 40 million as advances for future lease payments, invested about NIS 64 million in fixed assets, and hedged future euro-shekel payments through forward contracts. The project can improve automation, scale, and efficiency, especially if part of the site is subleased to CDSL. But it also sits directly on the capital and execution layers of the story.

The practical friction in Caesarea is still open. The agreement with CDSL and Super-Pharm included milestones for the warehouse buildout, and near the reporting date the company and CDSL were working on extending those milestones and updating other terms. Construction started in August 2024, and completion is expected only in December 2027. In other words, the project consumes cash now, while most of the operating value still sits several years out.

The second trigger is Mexico, and it looks like a step-change rather than a small bolt-on. In March 2026 Diplomat Distributors signed a non-binding memorandum of understanding to acquire 60% of two private companies in Mexico. The attached pro forma numbers indicate expected 2025 sales of USD 103 million, a 50% gross margin, and a 17.5% EBITDA margin. Total consideration is estimated at about USD 80 million, subject to adjustments, net debt, and an earn-out structure.

This could be a good deal, but it does not come for free. It is a real option to open a new territory in an area where Diplomat already has relevant know-how. But it also comes with a 120-day exclusivity period, due diligence, definitive agreements, regulatory approvals, and complete uncertainty around the final price and closing structure. When a company enters a deal of this scale in a year when working capital is already pressing on cash, the question is not only whether the move is strategic. It is whether the timing is right.

The third trigger is that the fourth quarter was clearly weaker. Fourth-quarter revenue stood at NIS 944.4 million, only slightly below the third quarter, but operating profit fell to NIS 22.9 million from NIS 39.6 million in Q3, and net profit fell to NIS 14.2 million from NIS 28.9 million. Even without a full quarterly 2024 comparison, the direction inside 2025 is clear enough.

The fourth quarter does not negate the full year, but it does change the order of questions. Instead of asking only whether Diplomat can still grow, the market now has to ask whether profitability and cash conversion were already softening into 2026.

Efficiency, Profitability, and Competition

The operating picture of 2025 looks positive at first glance. Revenue rose 5.6% to NIS 3.754 billion, and gross profit rose 6.8% to NIS 809.6 million. Gross margin also improved slightly to 21.6% from 21.3%. So the commercial platform is still adding volume without fully giving up margin on the way.

But the real story sits one layer below that. Selling, marketing, and distribution expense rose to NIS 472.2 million from NIS 431.8 million. The increase came mainly from transportation, wages, advertising, and depreciation tied to the renewed lease contract for the Israeli logistics center. G&A rose to NIS 202.3 million from NIS 174.4 million, mainly because of wages, professional services, IT costs, and a higher bad-debt provision. That is why reported operating profit fell to NIS 137.6 million even though gross profit improved.

The company itself explains that a direct comparison with 2024 is distorted because 2024 included a roughly NIS 47 million capital gain on the sale of the Tirat Carmel asset and a roughly NIS 9 million competition fine. But even after stripping those out, the picture is still not clean: normalized operating profit in 2025 was still lower by about NIS 15 million versus 2024. That is the heart of the read. 2025 was a growth year, but not an operating-leverage year.

Who benefited from growth, and who paid for it? Sales increased, but part of the price was paid through more transport, more advertising, more payroll, more doubtful-debt expense, and more operating complexity. That does not make growth bad, but it does make it lower quality than the top line suggests on first read.

Another point the market can easily miss is the quality of the bottom line. Net profit fell only to NIS 114.9 million from NIS 120.4 million, a milder decline than operating profit. The reason is that the finance layer helped this year: finance income rose to NIS 35.1 million mainly because of roughly NIS 29 million from the realization of the put option in Neve Pharma, while finance expense fell to NIS 35.5 million because of a lower revaluation burden on liabilities related to the purchase of minority stakes in Meditrend and Neve Pharma. Put simply, 2025 net profit looks more comfortable than 2025 operating profit.

The segment split shows how uneven the quality really is:

Israel is still a strong engine, but even there the margin fell to 4.7% from 6.8%. After removing the 2024 one-offs, management says Israel's operating profit was broadly unchanged, which means the conclusion is not collapse, but difficulty in extracting further operating leverage from growth. In South Africa, sales rose but the margin stayed weak at 1.9%, partly because of one-time costs from closing one of the distribution centers. In Georgia, sales barely moved and operating profit fell 41%, mainly because of weaker mix and higher operating expense.

The sharpest case is New Zealand. Sales there fell only slightly to NIS 262.2 million, but segment operating profit almost disappeared, down to just NIS 145 thousand. The company attributes that to gross-margin pressure, sales mix, higher discounts, and higher operating expense. But the market structure matters just as much: Foodstuffs North Island represented 26% of segment sales, Foodstuffs South Island 10%, Woolworths 29%, and Chemist Warehouse 14%. In other words, four customers accounted for 79% of New Zealand sales. In that kind of market, growth in new categories does not automatically translate into pricing power.

The concentration map makes the point sharper:

The key point is that Diplomat's breadth is real, but so is its concentration. That is not a contradiction. It is exactly why the market will keep focusing not just on how much the company sells, but on the terms under which it sells.

Cash Flow, Debt, and Capital Structure

This is where the active bottleneck sits. To read 2025 correctly, it is important to separate two things: the earning power of the business, and the all-in cash picture after real cash uses. The relevant framework here is all-in cash flexibility, not a narrow recurring-cash lens. The reason is simple: the real question in 2025 is not whether Diplomat produced profit, but how much cash was actually left after working capital, leases, capex, dividends, and acquisitions.

Operating cash flow fell to NIS 74.0 million from NIS 199.0 million. Net profit stood at NIS 114.9 million, but working capital absorbed about NIS 106.9 million: receivables consumed NIS 86.8 million, inventory consumed NIS 68.8 million, and only the increase in suppliers added back NIS 53.0 million. On top of that, net tax and interest cash outflow was about NIS 50.2 million.

That number matters because it tells you who funded growth. Receivables rose to NIS 501.9 million from NIS 424.8 million, and inventory rose to NIS 561.0 million from NIS 494.4 million. In Israel, inventory rose because of higher sales, new brands, and higher inventory days. In South Africa, management explicitly ties part of the inventory increase to a missed sales forecast. In New Zealand, the increase came from new brands and the first-time consolidation of CBL. Not all of the balance-sheet growth is simply healthy expansion.

Once the all-in cash picture is considered, the point becomes sharper. In 2025 Diplomat spent about NIS 84.0 million on fixed assets, about NIS 9.5 million on intangible assets, about NIS 56.1 million on lease payments, about NIS 56.5 million on dividends to shareholders, about NIS 15.8 million on activity acquisitions, and about NIS 9.0 million on the purchase of a newly consolidated company. On top of that, it paid NIS 40 million of future lease advances for Caesarea. Against all that stood only NIS 74.0 million of operating cash flow. So even if the company is profitable, it is not currently producing real excess cash after actual uses.

That is why the market cannot stop at the phrase "the group has positive working capital". It does. Working capital was positive at NIS 528.7 million. But it is made up mostly of receivables and inventory, not cash. That is a material distinction.

On the funding side, the balance sheet is still workable, but it is getting tighter. Short-term bank credit stood at NIS 224.5 million at year-end 2025, long-term bank loans at NIS 121.2 million, and lease liabilities at about NIS 170.9 million. Suppliers and service providers stood at NIS 338.2 million. Average short-term credit during the year rose to NIS 284.2 million from NIS 235.8 million, which fits exactly with the reading that expansion is now leaning more heavily on day-to-day financing.

Another point the market may miss is the role of the equity raise. In July 2025 Diplomat raised roughly NIS 100 million gross from three institutional investors at about NIS 46.5 per share. In theory, that should have created a wider capital cushion. In practice, management already explains that part of the money was used in Israel to reduce short-term debt, but the growth in working-capital needs and the Caesarea investment offset that benefit. In other words, the raise did not create a durable excess-cash position. It bought time.

This is also where created value and accessible value must be separated. Diplomat is building assets, adding brands, and widening its geographic reach. But that value first has to pass through inventory, receivables, leases, investment, and bank financing before it reaches common shareholders. That is why 2025 is not a weak year in terms of revenue, but it is a year in which financial flexibility became tighter.

Outlook

Four findings should frame 2026 from the start:

• This no longer looks like a clean growth year. It looks like a capital test.
• Caesarea can improve the economics of the platform, but in 2026 it mainly consumes cash.
• Mexico can open a new growth engine, but only if the deal structure does not add another layer of balance-sheet stress.
• The next set of reports will be judged more on cash flow, inventory, and New Zealand than on a few more points of revenue growth.

Without explicit numeric guidance, the right way to read 2026 is not through a revenue target, but through the type of year it is shaping up to be. For Diplomat, this looks like a capital-discipline year. There are enough growth drivers to justify cautious optimism, but also enough cash uses for the market to demand evidence rather than story.

Management continues to talk about business growth, new categories, third-party logistics, frozen and chilled products, and global development. All of that is consistent with Diplomat's multi-year strategy. But by now it is also clear that not every growth engine carries the same quality. Cyprus looks like growth that can still generate profit. New Zealand currently looks like growth that struggles to generate profit. Mexico, if it closes, will need to prove which group it belongs to.

What has to happen for the thesis to hold? First, receivables and inventory need to stop growing faster than cash is coming back in. Second, New Zealand needs to return to a meaningful operating contribution. It does not need to save the group, but it does need to stop signaling that geographic expansion is not automatically equal to economic value. Third, Caesarea needs to move ahead without execution surprises and without another major delay. Fourth, if Mexico moves from MOU to definitive agreement, the funding structure will matter at least as much as the purchase price.

What could improve the read in the short to medium term? A sharp recovery in cash flow in the next reports, or at least a clear stabilization. Any sign that the weak fourth quarter was an outlier rather than the start of a broader trend would matter. A constructive update on Caesarea, for example preserved timelines or better visibility around the CDSL layer, could also help.

What could weigh further? A Mexico deal that arrives too expensively or too aggressively financed, a widening of the Nutrilon recall beyond the immaterial impact disclosed so far, another step-up in receivables and inventory without matching improvement in suppliers or cash, or continued weakness in New Zealand. The company itself already says that if there is a very material decline in Nutrilon sales over time, especially if the recall broadens, profitability could be affected materially.

The conservative read, then, is that the market no longer needs proof that Diplomat can add brands and territories. It needs proof that the next phase will not undermine the business's most important quality, cash discipline.

Risks

The first risk is working capital and daily financing. Receivables and inventory already rose materially in 2025, and average short-term credit rose with them. This does not yet look like an immediate liquidity problem, but it does look like a business becoming more sensitive to any forecasting mistake in any territory.

The second risk is commercial and supplier concentration. In Israel, two large customers account together for 26% of segment sales. In Israel, 54% of purchases come from P&G. In South Africa, 82% of purchases come from Mondelēz. In Georgia, 77% of purchases come from P&G and Nestle combined. The company itself defines dependence on P&G and Mondelēz as one of its special group risks. That is a moat when it works, and a source of vulnerability when terms change.

The third risk is Caesarea as a strategically helpful but balance-sheet-heavy project. The new logistics center can improve automation, scale, and service, and it can support CDSL economics. But until late 2027 it remains, first of all, an execution project with future lease payments, automation capex, and hedging already visible on the balance sheet.

The fourth risk is Mexico as a capital-allocation test. A deal of this size can strengthen the international platform, but it can also demand capital exactly when the company has not yet restored stronger cash conversion. That risk will not be measured only at the EBITDA level of the acquired businesses, but at the level of the flexibility left for the listed company after closing.

The fifth risk is FX and rates. In Israel, Diplomat buys products mainly in shekels, but also in euros and dollars, and sells mainly in shekels. The company says it examines hedges for expected imports and already entered material euro-shekel forwards tied to Caesarea. The exposure exists, and even though 2025 rate changes did not materially affect finance expense, a business that funds working capital mainly through short-term credit remains highly sensitive to a different rate environment.

The sixth risk is foreign markets where pricing power sits with the customer. New Zealand is the clearest case. The company operates there through third-party logistics and faces a highly concentrated customer base. When segment profit nearly disappears, it becomes difficult to describe the problem as temporary noise without seeing actual recovery.

Conclusions

Diplomat ends 2025 as a bigger distribution company, but not as an easier company to read. Sales grew, Israel still carries the machine, and new brands plus geographic expansion continue to work at the revenue level. On the other hand, normalized operating profit weakened, cash flow fell sharply, and the fourth quarter showed that the year ended on a softer profitability run-rate.

Current thesis in one line: Diplomat remains a strong distribution platform, but in 2026 the test shifts from growth to capital discipline and cash conversion.

What changed versus 2024? The company moved from growth that still looked relatively comfortable to growth that already demands more capital. What is working operationally is still working, but less of it reaches shareholders as cash. The strongest counter-thesis is that 2025 was mainly a temporary investment year, and that Caesarea together with Mexico can build a larger profit platform in the years ahead. That is a serious argument, but for it to hold the company will need to show very soon that receivables, inventory, and New Zealand start behaving differently.

What can change the market reading over the short to medium term? A recovery in cash flow, better stability through the first half of 2026, and any Mexico update that does not stretch the balance sheet further. What would weaken the thesis? Another round of rising receivables and inventory, more weakness in New Zealand, or a large acquisition arriving before cash conversion improves.

Why does this matter? Because in distribution, business quality is not measured only by how many brands or countries a company holds. It is measured by whether that reach can still turn into recurring cash and stable returns on capital.